PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED
AML ETO t821 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED AML ETO t821 Gene Rearrangement Quantitative MRD Monitor Test Cost 1,350 د.إ Original price was: 1,350 د.إ.1,220 د.إCurrent price is: 1,220 د.إ.
Human Papilloma Virus Detection and Genotyping Qualitative PCR Test sale cost 1200 AED Human Papilloma Virus Detection and Genotyping Qualitative PCR Test Cost 1,300 د.إ Original price was: 1,300 د.إ.1,200 د.إCurrent price is: 1,200 د.إ.
Sale!

PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test Cost

Original price was: 1,350 د.إ.Current price is: 1,220 د.إ.

-10%

The PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative MRD Monitor Test is a specialized diagnostic tool used to detect and quantify the specific chromosomal abnormality associated with Acute Promyelocytic Leukemia (APL), a subtype of acute myeloid leukemia. This test identifies the presence of the PML-RARA fusion gene, which results from the translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12). This genetic anomaly is a hallmark of APL and plays a crucial role in the disease’s pathogenesis.

The test is highly sensitive and is utilized not only for diagnosing APL but also for monitoring minimal residual disease (MRD) during and after treatment. The ability to quantitatively measure the levels of the PML-RARA gene rearrangement allows healthcare providers to assess the effectiveness of therapy, detect early signs of relapse, and make informed decisions regarding patient management.

Performed at DNA Labs UAE, the test is offered at a cost of 1220 AED. This state-of-the-art facility ensures accurate and reliable results, employing advanced molecular techniques to support the precise diagnosis and monitoring of patients with APL. The quantitative aspect of this test is particularly valuable for tailoring patient-specific treatment plans and improving the overall prognosis by enabling timely interventions.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test

Welcome to DNA Labs UAE, where we offer the PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test. This test is used to monitor minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL).

Test Details

The PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative MRD monitor test is a diagnostic test used to monitor minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia (AML) characterized by the presence of a specific chromosomal translocation between the PML gene on chromosome 15 and the RARA gene on chromosome 17.

This translocation leads to the formation of the PML-RARA fusion gene, which plays a critical role in the development of APL. The quantitative MRD monitor test is performed using molecular techniques, such as polymerase chain reaction (PCR), to detect and quantify the presence of the PML-RARA fusion gene in the patient’s bone marrow or blood samples.

MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment and can potentially lead to disease relapse. Monitoring MRD levels during and after treatment is crucial in APL management, as it helps assess treatment response, predict relapse risk, and guide treatment decisions.

The quantitative MRD monitor test provides a quantitative measurement of the PML-RARA fusion gene, allowing clinicians to monitor MRD levels over time and make informed decisions regarding treatment adjustments or additional therapies.

Test Components

  • Price: 1220.0 AED
  • Sample Condition: 5 mL (3 mL min.) whole blood / Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.
  • Duly filled MRD Requisition form (Form 22) with historical data is mandatory.

Report Delivery

Sample Mon / Wed / Fri by 9 am; Report Tue / Thu / Sat

Method

Real Time PCR

Test Type

Cancer

Doctor

Hematologist

Test Department

MOLECULAR DIAGNOSTICS

Pre Test Information

Duly filled MRD Requisition form (Form 22) with historical data is mandatory.

Overall, the PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative MRD monitor test is an important tool in the management of APL, helping to monitor disease progression and guide treatment decisions to improve patient outcomes.

Test Name PML RARA t1517q22q12 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test
Components
Price 1220.0 AED
Sample Condition 5 mL (3 mL min.) whole blood \/ Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled MRD Requisition form (Form 22) with historical data is mandatory.
Report Delivery Sample Mon / Wed / Fri by 9 am; Report Tue / Thu / Sat
Method Real Time PCR
Test type Cancer
Doctor Hematologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled MRD Requisition form (Form 22) with historical data is mandatory.
Test Details

The PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative MRD monitor test is a diagnostic test used to monitor minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL).

APL is a subtype of acute myeloid leukemia (AML) characterized by the presence of a specific chromosomal translocation between the PML gene on chromosome 15 and the RARA gene on chromosome 17. This translocation leads to the formation of the PML-RARA fusion gene, which plays a critical role in the development of APL.

The quantitative MRD monitor test is performed using molecular techniques, such as polymerase chain reaction (PCR), to detect and quantify the presence of the PML-RARA fusion gene in the patient’s bone marrow or blood samples. MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment and can potentially lead to disease relapse.

Monitoring MRD levels during and after treatment is crucial in APL management, as it helps assess treatment response, predict relapse risk, and guide treatment decisions. The quantitative MRD monitor test provides a quantitative measurement of the PML-RARA fusion gene, allowing clinicians to monitor MRD levels over time and make informed decisions regarding treatment adjustments or additional therapies.

Overall, the PML-RARA t(15;17)(q22;q12) gene rearrangement quantitative MRD monitor test is an important tool in the management of APL, helping to monitor disease progression and guide treatment decisions to improve patient outcomes.

SKU: TEST-5640 Category:

Related products